{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=2", "query": { "intervention": "EYLEA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T04:00:25.695Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02976012", "title": "Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Endolaserless Vitrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Southeast Retina Center, Georgia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-06", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02976012" }, { "nct_id": "NCT02732899", "title": "Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age Related Macular Degeneration" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "EYLEA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Maturi, Raj K., M.D., P.C.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "50 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2016-04", "completion_date": "2017-04-04", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732899" }, { "nct_id": "NCT04964089", "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 557, "start_date": "2021-06-23", "completion_date": "2023-04-06", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 65, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964089" }, { "nct_id": "NCT06556368", "title": "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "Tarcocimab tedromer", "type": "DRUG" }, { "name": "Tabirafusp tedromer", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 675, "start_date": "2024-08-23", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 71, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06556368" }, { "nct_id": "NCT04989699", "title": "Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "OTX-TKI/Sham", "type": "DRUG" }, { "name": "Aflibercept/Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocular Therapeutix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 21, "start_date": "2021-07-28", "completion_date": "2023-12-18", "has_results": false, "last_update_posted_date": "2024-01-26", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 6, "location_summary": "Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04989699" }, { "nct_id": "NCT04527107", "title": "A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Diabetic Retinopathy", "Diabetic Macular Edema" ], "interventions": [ { "name": "THR-149 dose level 1", "type": "DRUG" }, { "name": "THR-149 dose level 2", "type": "DRUG" }, { "name": "THR-149 dose level 3", "type": "DRUG" }, { "name": "THR-149 0.13mg", "type": "DRUG" }, { "name": "THR-149 0.13mg + aflibercept 2mg", "type": "DRUG" }, { "name": "aflibercept 2mg + THR-149 0.13mg", "type": "DRUG" }, { "name": "Aflibercept 2mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oxurion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2020-07-31", "completion_date": "2023-11-22", "has_results": false, "last_update_posted_date": "2023-11-27", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04527107" }, { "nct_id": "NCT00320814", "title": "Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "VEGF Trap-Eye", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2006-04", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2011-06-10", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Charlotte, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320814" }, { "nct_id": "NCT03297684", "title": "Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept Injection [Eylea]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Eye Research Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 40, "start_date": "2018-04-11", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 1, "location_summary": "South Dartmouth, Massachusetts", "locations": [ { "city": "South Dartmouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297684" }, { "nct_id": "NCT01495221", "title": "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)" ], "interventions": [ { "name": "Alfilbercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitreous -Retina- Macula Consultants of New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 9, "start_date": "2011-12", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495221" }, { "nct_id": "NCT05769153", "title": "Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "AR-14034 SR implant lower dose", "type": "DRUG" }, { "name": "AR-14034 SR implant higher dose", "type": "DRUG" }, { "name": "AR-14034 SR implant", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" }, { "name": "Sham procedure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 139, "start_date": "2023-12-06", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-24T04:00:25.695Z", "location_count": 42, "location_summary": "Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769153" } ] }